<DOC>
	<DOCNO>NCT01294423</DOCNO>
	<brief_summary>This 24-week randomised , multi-centre phase III study evaluate efficacy safety dapagliflozin monotherapy Japanese subject Type 2 diabetes mellitus inadequate glycemic control diet exercise .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Men woman age ≥20 year old ( Either gender need 40 % high total number treat subject ) diagnose type 2 DM ; ≥6.5 % ≤10 % 1 week randomization Type 1 diabetes mellitus FPG &gt; 240 mg/dL randomization Subjects history unstable rapidly progress renal disease Subjects severe hepatic insufficiency and/or significant abnormal liver function Significant cardiovascular history</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phase3</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Type2 Diabetes Mellitus</keyword>
</DOC>